tbuckley/cabot-search huggingface dataset:
Outcome of metastatic colorectal cancer patients receiving second line chemotherapy in Marmara University Hospital
Authors: F. Dane, M. Gumus, A. Ozturk, F. Yumuk, S. Iyikesici, G. Basaran, D. Cabuk, M. Teomete, N. S. Turhal
Journal: Journal of Clinical Oncology (2007)

14588 Background: With the development of oxaliplatin and irinotecan, multiple effective regimens are now available in advanced colorectal cancer (CRC), both as first- and second-line treatment options. Exposure to all of the active drugs is effective in prolonging overall survival (OS) and time to progression (TTP). There are limited studies, if any, analyzing the outcome of second line chemotherapy in metastatic CRC in Turkey. Thus, we aimed to evaluate the outcome of second-line treatments in metastatic CRC patients. Methods: Among 173 patients with metastatic CRC who were given first line chemotherapy 106 (47 female, 59 male) were administered second line treatment after progression. All patients histologically confirmed colorectal adenocarcinoma with ECOG performance score of 2 or lower, and received second line therapy for metastatic CRC after experienced disease progression during or following treatment with first-line therapy were entered the study. The patients were evaluated clinically and radiologically after each three-cycle period, and chemotherapy was changed or stopped if the cancer has progressed. Age, gender, grade, chemotherapy type (combination vs single agent), lymphatic, vascular, and perineural invasion, were analyzed as prognostic factors. Results: At a median follow up of 10 (range 1–40) months from the start of second line chemotherapy median TTP and OS time were 5 and 16 months respectively. Median age was 62 years (range 27–89). After second line therapy 16% of the patient had objective response rate (0.9% complete responses plus 15.1% partial responses), 37.7% had stable disease resulting in a tumor control rate of 53.7%, and 46.2% had progressive disease. One-year progression free survival and OS rates were 15 % and 53.5%, respectively. No difference was seen in the survival of patients received combination or single agent second line chemotherapy (p=0.14). Overall, over 12% of the patients suffered from grade 3 or 4 adverse effects. In multivariate analysis histological grade (p=0.015) was the only independent prognostic factor for survival. Conclusion: The survival outcome and adverse effects of second line treatments in Turkish patients in our department with metastatic CRC is consistent with the worlds’ literature. No significant financial relationships to disclose.
Impact of socioeconomic factors on the incidence of urothelial cell carcinoma in Germany.
Authors: Maximilian Peter Johannes Karl Brandt, Kilian Gust, Stefan Vallo, Jens Mani, Claudia Bartsch, Adrien Schertzer, Igor Tsaur, Michael Andreas Reiter, David Schilling, Axel Haferkamp, Eva Herrmann, Georg Bartsch
Journal: Journal of Clinical Oncology (2015)

348 Background: In the European Union (EU) differences in tumor incidence for urothelial cell carcinoma (UCC) have been reported. Besides occupational exposure, tobacco smoke and nitrite have been identified as risk factors for UCC. No study has evaluated the regional incidence of UCC in Germany in consideration of socioeconomic landscape. We investigated if a different allocation to agriculture (A), industrial use (I) and land settlement (S) are associated with the incidence of UCC. Methods: In collaboration with the German Centre for Cancer Registry Data, Robert Koch Institute, Berlin, all new cases of UCC between 2003 and 2010 were included, with partly dropped out information due to incomplete reporting. Kulldorff spatial cluster test was used to detect clusters with high incidence rates. Furthermore, information within the different administrative areas of Germany from 2010 for land use factors A, I and S were obtained from the Regional Database Germany, and calculated as both, a proportion of the total area of the respective administrative region and as a smoothed proportion including values from neighbouring regions. A negative binomial model was used to test the association of the area information in addition to the expected cases information for age and sex distribution. All tests were two-sided and a significance level of α=5% was used. Results: In a follow up of 437,847,835 person years, 171,086 incident cases of UCC were identified. Cluster analysis revealed areas with a significant higher incidence of UCC than others (p=0.0002). Multivariate analysis on land use (as smoothed proportion) in all available counties showed that each such factor is an independent risk factor for UCC (p&lt; 0.00001, respectively). The interquartile range of the respective proportions and the relative risk (RR) for raising the respective proportion from first to third quantile of different land use were 35%-60% (RR 1.10), 0.5%-2.3% (RR 1.07) and 10%-29% (RR 1.21) for all three factors A, I, and S, respectively. Conclusions: This study displays regional differences in UCC incidence in Germany. Furthermore, results suggest that environmental exposure based on socioeconomic factors may present a relevant carcinogenic risk for UCC.
Non-pegylated lyposomal doxorubicin, cyclophosphamide, vincristine, prednisone, and rituximab (R-COMP) as initial treatment for patients with splenic marginal zone lymphoma (SMZL): A GISL study
Authors: E. Iannitto, S. Luminari, C. Mammi, V. Minardi, F. Merli, F. Angrilli, C. Stelitano, M. Cesaretti, G. Franco, A. M. Carella, M. Federico
Journal: Journal of Clinical Oncology (2007)

18502 Background: SMZL is an indolent lymphoma, presenting with massive splenomegaly generally associated with intrasinusoidal bone marrow infiltration. The encapsulation of doxorubicin into non-pegylated liposomes allows targeting of the drug to affected organs including spleen, lymphnodes and bone marrow. Methods: In 2005, the GISL started a phase II study for the treatment of patients with histologically confirmed SMZL, investigating safety and clinical profile of 6 courses of a modified R-CHOP regimen in which standard doxorubicin was substituted with non pegylated lyposomal doxorubicin (NPLD) used at the same doses (50 mg/m 2 ) (R-COMP). Main inclusion criteria were age &gt;18 yrs, normal cardiac function and active disease (at least one of the following; Hb &lt;10 g/dl; plt &lt;100,000/mmc, symptomatic splenomegaly, elevated LDH, B symptoms, extrasplenic disease, LDT &lt;12 months). Splenectomy was allowed prior to treatment start only in case of symptomatic spleen enlargement. The study was planned according to a two-stage Simon design using overall response rate as primary endpoint. We present the results of the analysis performed after the completion of study stage 1. The access to stage 2 is allowed if at least 12 responses are recorded among among the first 19 evaluable cases. Results: As of January 2007, 20 patient were enrolled with the following characteristics; median age 63 years (30–80), Hb &lt;10 g/dl in 20%, Lymphocytes &gt; 5,000/mmc in 65%, elevated LDH in 65%; 2 patients were splenectomized before treatment start. One patient was not available for response assessment. A clinical response was observed in all remaining 19 cases (ORR 100%); 12 (63%) cases obtained a CR. So far only one patient progressed at +1 month from treatment. Treatment was well tolerated with grade III/IV neutropenia in 8 patients (42%), grade 3 pulmonary toxicity in 1 patient and grade 2 peripheral neuropathy in 5 cases. In one case a reversible cardiac failure was reported after 1 month from the end of treatment. Conclusions: In conclusion 6 cycles of R-COMP combination represent a safe and promising treatment option for patients with clinically active SMZL. No significant financial relationships to disclose.
Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy
Authors: J P Guastalla, C Lhomme, P Kerbrat, F Mayer, M Namer, P Goupil, P Charrot, J F Heron, M Chazard, I Richard
Journal: Annals of Oncology (1994)
Abstract PR10: Re-engineering immunity to treat pancreas cancer
Authors: Ingunn M. Stromnes, Scott Brockenbrough, Thomas M. Schmitt, Jennifer D. Hotes, Markus A. Carlson, Carlos Cuevos, Philip D. Greenberg, Sunil R. Hingorani
Journal: Cancer Research (2015)

Abstract Designing T cells to effectively and safely target pancreatic ductal adenocarcinoma (PDA) has therapeutic promise, especially if combined with approaches to modify the desmoplastic and immunosuppressive tumor environment. We cloned and expressed a panel of enhanced affinity PDA-specific T cell receptors and the fate and function of such engineered tumor-specific T cells have been tracked in vivo using a genetically engineered mouse model of PDA (KPC) that we have backcrossed to C57Bl/6. Engineered T cells preferentially accumulate in PDA and express markers indicative of antigen recognition only in tumors and not peripheral sites. The transfer of engineered PDA-specific T cells significantly increased tumor cell apoptosis and remodeled the tumor matrix. However, over-time, persisting tumor-infiltrating, engineered T cells expressed markers associated with chronic antigen signaling and exhibited dysfunction as compared to donor T cells isolated from the periphery of the same host, indicating selective immunosuppression at the tumor site. Ongoing studies have identified distinct populations of immunosuppressive cells in PDA that are selectively being targeted to reveal how to sustain and enhance the activity of tumor-specific T cells. Our studies aim to elucidate the cellular and molecular signals impacting the activity of T cells specific to naturally occurring antigens overexpressed by PDA that will help to provide essential insights for the engineering of human lymphocytes and the design of clinical trials to translate our findings to patient treatment. This abstract is also presented as Poster B58. Citation Format: Ingunn M. Stromnes, Scott Brockenbrough, Thomas M. Schmitt, Jennifer D. Hotes, Markus A. Carlson, Carlos Cuevos, Philip D. Greenberg, Sunil R. Hingorani. Re-engineering immunity to treat pancreas cancer. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr PR10.
Pre-radiation chemotherapy with ACNU-CDDP in patients with newly diagnosed glioblastoma: A retrospective analysis
Authors: C. Kim, J. Han, C. Park, S. Lee, D. Kim, S. Paek, D. Kim, D. Heo, I. Kim, H. Jung
Journal: Journal of Clinical Oncology (2008)

2067 Background: We evaluated the benefit of pre-radiation chemotherapy with ACNU(nimustine) plus CDDP(cisplatin) for patients with newly diagnosed glioblastoma by retrospective analysis. Methods: A total of 151 patients were newly confirmed to have glioblastoma between January 2000 and December 2004. All patients underwent surgical resection; complete resection in 38(25.2%), incomplete resection in 73(48.3%), and biopsy in 40(26.5%). Pre-radiation chemotherapy using ACNU-CDDP was administered as an initial adjuvant management for 87(57.6%) patients (ACNU-CDDP group), radiation therapy was performed in 31(20.5%) patients (RT group) and the rest 33 (21.9%) patients were treated with other regimens or refused further treatment. Results: The median survival time was 13 months (95% CI, 11.29–14.71), and the overall survival rate was 54.0% at 1 year, 21.3% at 2 years. Difference of the median survival time between complete resection group and biopsy group, and between ACNU-CDDP group and RT group was significant (15.0 months vs 10 months, p=0.028; 16.0 months vs 12.0 months, p=0.036) in the univariate analyses. Even in the multivariate analysis, pre-radiation chemotherapy using ACNU-CDDP showed significant effect on survival prolongation (HR=0.628, p=0.042). Usage of temozolomide for adjuvant or salvage management also had independent significant positive effect on the survival (HR=0.511, p=0.006). Grade 3 and 4 hematologic toxicities occurred in 28 (32.1%) patient of ACNU-CDDP group. However, there was no treatment-related death. Conclusions: Pre-radiation chemotherapy with ACNU-CDDP as an initial management is independently beneficial in survival prolongation with tolerable treatment-related toxicities in patients with newly diagnosed glioblastomas No significant financial relationships to disclose.
Changes in the treatment of asthma in Spain in the last twenty years. A population based study (ECRHS)
Authors: Jesús Martínez-Moratalla Rovira, Esperanza Mancebo Gilabert, Anne Elie Carsin, José Luis Sánchez Ramos, Josep María Antó Boqué, Isabel Urrutia Landa
Journal: European Respiratory Journal (2014)

The objective of the current study is to evaluate changes in the treatment of asthma at the individual and populational levels over the span of 20 years in the european community respiratory health surveys (ECRHS).  Individuals were selected based on a validated questionnaire, in which physician diagnosed of asthma (PDA) was present in at least one of the studies (1992,2002,2012). In this analysis, the recommended treatment for asthma was classified in three tiers, among those exclusively: 1) Inhaled beta 2 adrenergic bronchodilator as the only treatment; 2) only corticosteroids inhaled, or combined with other treatments except oral corticosteroids, and 3) oral corticosteroids although it is associated with other treatments.  Our conclusion is that more adequate treatment of asthma has occurred in Spain over the course of the last twenty years.
Decreased PET SUV after induction chemotherapy is associated with improved survival in malignant pleural mesothelioma (MPM)
Authors: R. M. Flores, T. Akhurst, L. Krug, M. Gonen, J. Dycoco, K. Rosenzweig, S. M. Larson, R. J. Downey, V. W. Rusch
Journal: Journal of Clinical Oncology (2005)

7066 Background: Our prior studies showed that PET detects metastatic disease1 not identified by CT and that PET SUV predicts survival2. However, no study has yet shown whether change in SUV correlates with response to chemotherapy or survival. We prospectively evaluated PET before and after induction therapy in MPM patients subsequently undergoing surgery. Methods: Patients with MPM who were enrolled in clinical trials of induction chemotherapy followed by extrapleural pneumonectomy(EPP) and hemithoracic radiation and who had PET scans before and after chemotherapy. Patients fasted and received a minimum of 10 mCi of F18-flourodeoxyglucose. Whole-body emission studies were acquired, followed by whole-body transmission scans with iterative reconstruction. Survival was analyzed by Kaplan Meier. Results: From 1999–2004, 24 consecutive patients (19 men and 5 women; median age 62 years) had PET scans before and after cisplatin-based induction chemotherapy. EPP was performed in 15, pleurectomy/decortication in 1, and biopsy only in 8. Histology was 17 epithelioid and 6 non-epithelioid. AJCC stage II was observed in 8 patients, stage III in 5, and stage IV in 11. The mean change in SUV from baseline was 0.125; maximum decrease was 9 and maximum increase was 19, with a median follow-up of 11 months. Patients with a decrease in SUV (n=16) after chemotherapy had a significantly better survival compared to patients with an increase in SUV (n=8). Median survival was 58.5 months versus 34.8 months, respectively (log rank p-value=0.03) Conclusions: A decrease in PET SUV after induction chemotherapy is associated with a significant improvement in survival. These findings suggest that PET is useful in restaging patients after induction therapy and selecting them for surgery. 1.Flores et al. JTCVS 2003;126;11–16. 2.Flores et al. ASCO Proc; 2003.#2495 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly
Cyberknife stereotactic radiotherapy for isolated nodal recurrence of prostate cancer.
Authors: Beatrice Detti, Pierluigi Bonomo, Irene Giacomelli, Sabrina Cappelli, Linda Poggesi, Davide Franceschini, Muhammed Ali Muhammed Baki, Marco Carini, Nicita Giulio, Sergio Serni, Valentina Baldazzi, Di Brina Lucia, Anna Mancuso, Monteleone Pasquetti Eleonora, Giulio Alberto Carta, Cristina Muntoni, Cinzia Ciabatti, Lorenzo Livi
Journal: Journal of Clinical Oncology (2015)

257 Background: We report a preliminary clinical experience in stereotactic body radiation therapy (SBRT) delivered using Cyberknife for isolated nodal metastases from prostate cancer. Methods: Between November 2011 and December 2013, 30 patients (39 lesions) were treated with SRT for recurrent prostate cancer with isolated nodal metastases. Prescribed doses and schedules of fractionation varied according to site of disease, ranging from 24 Gy in 1 fraction to 36 Gy in 3 fractions. Most commonly used schedules were 30 Gy in 3 fractions and 36 in Gy in 3 fractions on alternating days. Biochemical response, acute and late toxicity were analyzed. Results: At a median follow-up of 12 months (range: 2-24.9), reduction of PSA ≥ 50% was observed in 18 cases, reduction &lt; 50% was observed in 7, while PSA was stable in 1 case and raised in 8 cases. At the time of analysis, among the 30 patients treated, 2 were dead for systemic disease; 12 patients experienced a relapse of disease in other sites and were treated with HT and salvage chemotherapy. Sixteen patients were still free of disease. In 24 cases, imaging evaluation three months after treatment was available. No in field recurrence was detected, CR was detected in three cases, PR in 14 and SD in 8 patients. The treatment with Cyberknife was well tolerated: one patient experienced G2 acute genitourinary toxicity. Late toxicity was evaluated in patients with more than 3 months of follow up and only one complained G1 proctitis. We did not observe any acute or late severe toxicity (≥G3). Conclusions: Our experience shows that SRT with Cyberknife for isolated nodal relapse from prostate cancer is a safe treatment, with promising results in terms of efficacy.
Pet ownership in eight European birth cohorts - results of a GA(2)LEN initiative
Authors: S. Roll, T. Keil, E. Eller, C. Bindslev-Jensen, U. Kraemer, C. Chen, A. von Berg, H. Smit, A. Wijga, K. L. Carlsen, K. Carlsen, M. Wickman, I. Kull, M. Mommers, C. Thijs, F. Forastiero, D. Porta, I. Fantin, F. Bravi, Kristel Van Steen, S. Willich, U. Wahn, S. Lau, J. Heinrich
Journal: Allergy (2007)
Efficacy and Safety of Apixaban in Patients With Atrial Fibrillation According to Sex : Results From the ARISTOTLE Trial
Authors: Dragos Vinereanu, Susanna R. Stevens, John H. Alexander, Sana M. Al-Khatib, Alvaro Avezum, Cecilia Bahit, Christopher B. Granger, Renato D. Lopes, Sigrun Halvorsen, Michael Hanna, Steen Husted, Elaine M. Hylek, Andrei D. Margulescu, Lars Wallentin, Dan Atar
Journal: Circulation (2013)

Efficacy and Safety of Apixaban in Patients With Atrial Fibrillation According to Sex : Results From the ARISTOTLE Trial
Evaluation of docetaxel and vinorelbine plus sargramostim in patients with malignant melanoma
Authors: J. P. Fruehauf, K. Kong, J. G. Jackowatz
Journal: Journal of Clinical Oncology (2004)

7565 Background: There are an estimated 40,000 new cases of malignant melanoma and 7000 deaths annually in the U.S. In the past decade the incidence of melanoma has increased more rapidly than any other cancer except lung cancer in women. Current chemotherapy regimens offer limited benefits to patients with metastatic disease. More effective and less toxic treatments are needed for these patients. In preclinical studies, we observed that docetaxel and vinorelbine showed significant independent in vitro activity against melanoma specimens. Photiou et al reported that docetaxel and vinorelbine act synergistically against melanoma cell lines (Eur J Cancer 33:463, 1997). Further, Spitler et al have reported that GM-CSF may be an effective adjuvant in Stage III and IV patients after surgery (JCO 18:1614, 2000). Methods: We therefore piloted the DVS regimen of docetaxel 40 mg/m2 IV over 1 hour, vinorelbine 30 mg/m2 IV over 6–10 min every 14 days and Sargramostim 250 mcg/m2 SQ QD on days 2–12 in the treatment of patients with Stage IV melanoma with measurable disease either after biochemotherapy (n=8) or as an initial treatment modality (n=2). Response rates were determined by CT scans using criteria for partial response of 50% or greater reduction in one dimension of the dominant mass lasting more than 4 weeks. Time to progression was determined from the time DVS treatment was initiated until radiological evidence of an increase of >25% in one dimension of the dominant mass. Results: We report here results for the initial 10 cases. No grade III or IV toxicities were encountered. Of the 10 patients evaluable for response, 5 were partial responders (50% RR). Time to progression (TTP) for the 10 cases were 2M, 2.5M, 5M, 5M, 6M, 8M, 8M, 9M, 18M (No prior treatment), 26+M (no-prior treatment). The median TTP was 8 months, which is somewhat better than the 7.5 months for median survival reported by Eaton et al for biochemotherapy (Clin Cancer Res 8:3075, 2002). Conclusions: The DVS regimen was active against both previously treated and untreated patients with advanced melanoma. A larger study to confirm the activity of the DVS regimen for stage IV melanoma is currently underway. No significant financial relationships to disclose.
Abstract 13713: Genetic Polymorphism and Relationship to Cystatin C Concentrations and Outcome - Results From the Platelet Inhibition and Patient Outcomes Study
Authors: Axel Åkerblom, Lars Wallentin, Agneta Siegbahn, Richard C. Becker, Andrzej Budaj, Anders Himmelmann, Steen Husted, Robert F. Storey, Niclas Eriksson, Åsa Johansson, Stefan K. James
Journal: Circulation (2013)

Genetic Polymorphism and Relationship to Cystatin C Concentrations and Outcome - Results From the Platelet Inhibition and Patient Outcomes Study
Combined topotecan and lapatinib in patients with early recurrent ovarian or peritoneal cancer after first line of platinum-based chemotherapy: A French FEDEGYN-FNCLCC phase II trial
Authors: F. Joly, B. Weber, P. Pautier, M. Fabbro, F. Selle, S. Krieger, A. Leconte, H. Bourgeois, M. Henry-Amar
Journal: Journal of Clinical Oncology (2009)

5555 Background: High HER1 expression is associated with poor prognosis. Preliminary data have shown links between HER1 expression and topotecan efficacy. The objective of the trial was to evaluate the efficacy of the association of topotecan and lapatinib in non-HER screened patients who failed first line platinum-based chemotherapy within 12 months. Methods: Chemotherapy consisted of 4-week course of topotecan (d1, d8, d15, 3.2 mg/m 2 IV) and lapatinib (1250 mg/d PO). Response was assessed using RECIST or RUSTIN criteria. The primary objective was global response (GR, i.e. CR, PR, and SD). Biomarker profiles were evaluated according treatment response. A two-step phase II trial was designed to include 54 patients assuming a GR rate of 75% for the combination compared to 55% for topotecan alone. Results: From March to September 2008, 39 patients (37 ovarian and 2 peritoneal carcinomas), median age 60 (18 to 80), were included in 16 institutions. Patients presented with FIGO stage I (n = 1), II (n = 2), III (n = 29), and IV (n = 7) disease. Twenty and 19 patients had disease relapse occurring &lt; 6 and 6–12 months after initial chemotherapy respectively. 2 patients were non evaluable. After 1 to 8 cycles (median 2) of topotecan-lapatinib there were 0/2 PR, 7/9 SD, 12/7 progressions in patients who failed &lt;6 or 6–12 months respectively. The GR rate was 46% (35 and 58%; 95% confidence limits, 30–63%) and the trial was prematurely stopped. Three patients developed toxicity leading to treatment discontinuation after 3 cycles. Biological data will be presented at meeting. Conclusions: Combined topotecan and lapatinib is associated with modest GR rate. Biological profiles of responders are pending. No significant financial relationships to disclose.